Lymphoma prognostic methods and kits
A method for differentiating forms of lymphoma involves analyzing a tumor tissue sample from a subject for expression of CD28, ABCA5, CCDC3, and SMOC2. The CD28:ABCA5 expression ratio differentiates T-cell tumors from B-cell tumors. The CCDC3:SMOC2 expression ratio differentiates different T-cell tumors. The method can further include administering to the subject from whom the sample was obtained an appropriate treatment for the form lymphoma identified by performing the method.
1. A method to distinguish lymphomas comprising:
analyzing a tumor tissue sample from a subject for expression of CD28, ABCA5, CCDC3, and SMOC2,
calculating an expression ratio between CD28 and ABCA5;
calculating an expression ratio between CCDS3 and SMOC2;
wherein:
a CD28:ABCA5 expression ratio greater than 1.0 in the tumor sample is indicative of a T-cell tumor;
a CD28:ABCA5 expression ratio less than 1.0 in the tumor tissue sample is indicative of a B-cell tumor;
and if a T-cell tumor is indicated, wherein:
a CCDC3:SMOC2 expression ratio of greater than 1.0 is indicative of a low grade T-cell tumor; and
a CCDC3:SMOC2 expression ratio of less than 1.0 is indicative of a high grade T-cell tumor.
2. The method of claim 1 wherein analyzing a tumor tissue sample from a subject for expression of at least two biomarkers comprises analyzing RNA.
3. The method of claim 2 wherein analyzing RNA comprises qRT-PCR.
4. The method of claim 1 wherein analyzing a tumor tissue sample from a subject for expression of at least two biomarkers comprises analyzing protein expression.
5. The method of claim 1 wherein the tissue sample comprises a fine needle aspirate sample or a biopsy sample.
6. The method of claim 1 wherein the T-cell tumor comprises lymphoblastic T-cell lymphoma, T-zone lymphoma, or peripheral T-cell lymphoma, not otherwise specified.
7. The method of claim 1 wherein the B-cell tumor comprises Burkitt's lymphoma, diffuse large B-cell lymphoma, or marginal B-cell lymphoma.
8. The method of claim 1 wherein the low grade T-cell tumor comprises T-zone lymphoma.
9. The method of claim 1 wherein the high grade T-cell tumor comprises lymphoblastic T-cell lymphoma or peripheral T-cell lymphoma, not otherwise specified.
10. The method of claim 1 further comprising providing conservative treatment to a subject identified as having a low grade T-cell tumor, providing aggressive treatment to a subject having a high grade T-cell tumor, or standard of care treatment to a subject having a B-cell tumor.
11. The method of claim 10 wherein conservative treatment comprises at least one of: watchful waiting, administering prednisone to the subject, and administering chlorambucil to the subject.
12. The method of claim 11 wherein conservative treatment comprises administering to the subject a combination of prednisone and chlorambucil.
13. The method of claim 10 wherein aggressive treatment comprises at least one of: administering lomustine to the subject and administering adriamycin to the subject.
14. The method of claim 13 wherein aggressive treatment comprises administering to the subject a combination of lomustine and adriamycin.